0.5 mg / 2.5 mg Nebuliser Solution
Ipratropium bromide + Salbutamol

Combiprasal® Nebuliser Solution

spacer device
Key Features
  • COMBIPRASAL is indicated for the management of bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD) who require regular treatment with both ipratropium bromide and salbutamol.
  • Cost effective than generic combination therapy with improved patient compliance
  • Method of administration - Inhalation use only.
  • Bioequivalent to the originator brand
  • Available Strengths :0.5 mg / 2.5 mg Nebuliser Solution
  • Pack Size :60 x 2.5ml Vials
  • Dose :One single-dose container three or four times daily.
  • POM

Ipratropium Bromide + Salbutamol cost effectiveness with COMBIPRASAL Nebuliser Solution

Visit EMC for more detail :